Dermata Therapeutics, Inc. 8-K Summary
Business Context and Reporting Period
This Form 8-K Current Report, dated February 8, 2023, covers a special meeting of stockholders held by Dermata Therapeutics, Inc. on that same date. The company is an emerging growth company incorporated in Delaware with its principal executive offices in San Diego, California.
Key Financial Metrics
This filing does not provide financial performance data such as revenue, profit, cash flow, margins, debt, or liquidity. The report focuses exclusively on corporate governance actions regarding capital structure.
Material Changes
The primary material change reported is the stockholder approval of a reverse stock split. The company's Amended and Restated Certificate of Incorporation was amended to authorize a reverse split of its common stock at a ratio ranging from 1-for-2 to 1-for-40. The exact ratio is to be determined by the Board of Directors without further stockholder approval. Additionally, stockholders approved the adjournment of the meeting if necessary to secure the required votes.
Guidance, Outlook, and Risks
The filing contains no management commentary on future financial guidance, operational outlook, or specific risk factors. The only contingency noted is the approval of the adjournment proposal to ensure the reverse stock split could be enacted if initial voting was insufficient.
Key Facts for Investor Verification
- Reverse Stock Split Approved: Stockholders authorized a reverse split between 1:2 and 1:40.
- Board Discretion: The Board of Directors has the authority to set the final split ratio without further voting.
- Voting Results: Proposal 1 (Reverse Split) passed with 7,622,928 votes for, 135,481 against, and 39,669 abstentions.
- Adjournment Approved: Proposal 2 (Adjournment) passed with 7,681,932 votes for, 87,554 against, and 28,592 abstentions.
- Record Date: Voting was based on 12,321,848 shares outstanding as of December 28, 2022.